RecruitingPhase 2NCT05894018

Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue Sarcoma

A Phase II Clinical Trial Evaluating the Safety and Efficacy of Radioactive Particle and Fluzoparib Combination Therapy in the Treatment of Advanced Unresectable Soft Tissue Sarcoma

Sponsor

Fujun Zhang

Enrollment

32 participants

Start Date

Jun 29, 2023

Study Type

INTERVENTIONAL

Conditions

Sarcoma,Soft Tissue Brachytherapy Poly(ADP-ribose) Polymerase Inhibitors

Summary

To evaluate the effectiveness and safety of radioactive particles in combination with the PARP inhibitor fluzoparib in the treatment of advanced inoperable soft tissue sarcoma.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests a combination of radioactive seed implants (brachytherapy using iodine-125) and fluzoparib (a PARP inhibitor drug) for advanced soft tissue sarcomas that cannot be surgically removed. **You may be eligible if...** - You are 18 or older - You have pathologically confirmed soft tissue sarcoma that is advanced and cannot be surgically removed - You have at least one measurable tumor on CT or MRI - You have received prior standard treatments **You may NOT be eligible if...** - Your sarcoma has not been confirmed by biopsy - You have no measurable tumor on imaging - You have serious health problems that would make this treatment unsafe Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.